Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remternetug Versus Placebo in Early Alzheimer's Disease
NCT06653153Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2024
- Primary completion
- Apr 2029
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 3 trial of remternetug in Alzheimer's disease (AD), sponsored by Eli Lilly and Company. Started Oct 2024; status: active, not recruiting.
02
Drugs
remternetug
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06653153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06653153.